A sub-assembly of a cassette of a medicament delivery device

Abstract

A sub-assembly of a cassette of a medicament delivery device, the sub-assembly comprising: a body extending along a longitudinal axis between a proximal end and a distal end; a rotator attached to the body and being rotatable relative to the body around the longitudinal axis from a first position to a second position; wherein one of the body and the rotator comprises a connector configured to be connected to a counter connector of a drive unit of the medicament delivery device via a predetermined rotation between the connector and the counter connector when the rotator is rotated from the first position to the second position such that the body is configured to be fixedly attached to the drive unit of the medicament delivery device; and wherein one of the body and the rotator comprises a protrusion, and the other one of the body and the rotator comprises an interacting surface configured to interact with the protrusion when the rotator is rotated from the first position to the second position such that a tactile indication is generated between the protrusion and the interacting surface.

Description

[0001] TITLE

[0002] A sub-assembly of a cassette of a medicament delivery device

[0003] TECHNICAL FIELD

[0004] The present disclosure generally relates to a sub-assembly of a cassette of a medicament delivery device, and particularly to a sub-assembly comprises a body and a rotator rotatable relative to the body.

[0005] BACKGROUND

[0006] Medicament delivery devices such as auto- injectors, inhalers and on-body devices are generally known for the self-administration of a medicament by patients without formal medical training. Therefore, those medicament delivery devices usually comprise multiple automatic functions and are usually delivered to end-users with prefilled medicament containers. Although there are many well-designed medicament delivery devices usually with multiple automatic functions in the market, there are still long-term remaining issues to be solved.

[0007] For example, some medicament delivery devices are designed to deliver more than one dose to an end user. It is common that this type of medicament delivery device is formed by a drive unit and a disposable cassette being attached to the drive unit. It is common that the disposable cassette is configured to be attached by an end user. Thus, it is desirable to have some designs that can provide indication to the end user and therefore guide the end user to properly attach the cassette to the drive unit. It is common that the drive unit is reusable. Thus, the drive unit can be equipped with more sophisticated designs, e.g., a motor, sensors... etc., that are contributed to better performance of the medicament delivery operation.

[0008] It has been appreciated that improved solutions for providing a reliable prevention mechanism for the above-mentioned issue that can be used with a more powerful power source.

[0009] SUMMARY

[0010] The invention is defined by the appended claims, to which reference should now be made.In the present disclosure, when the term “distal direction” is used, this refers to the direction pointing away from the dose delivery site during use of the medicament delivery device. When the term “distal part / end” is used, this refers to the part / end of the delivery device, or the parts / ends of the members thereof, which under use of the medicament delivery device is / are located furthest away from the dose delivery site. Correspondingly, when the term “proximal direction” is used, this refers to the direction pointing towards the dose delivery site during use of the medicament delivery device. When the term “proximal part / end” is used, this refers to the part / end of the delivery device, or the parts / ends of the members thereof, which under use of the medicament delivery device is / are located closest to the dose delivery site.

[0011] Further, the term “longitudinal”, “longitudinally”, “axially” or “axial” refer to a direction extending from the proximal end to the distal end, typically along the device or components thereof in the direction of the longest extension of the device and / or component.

[0012] Similarly, the terms “transverse”, “transversal” and “transversally” refer to a direction generally perpendicular to the longitudinal direction.

[0013] Further, the terms “circumference”, “circumferential”, or “circumferentially” refer to a circumference or a circumferential direction relative to an axis, typically a central axis extending in the direction of the longest extension of the device and / or component. Similarly, “radial” or “radially” refer to a direction extending radially relative to the axis, and “rotation”, “rotational” and “rotationally” refer to rotation relative to the axis.

[0014] There is hence provided a sub-assembly of a cassette of a medicament delivery device, the sub-assembly comprising: a body extending along a longitudinal axis between a proximal end and a distal end; and a rotator attached to the body and being rotatable relative to the body around the longitudinal axis from a first position to a second position. One of the body and the rotator comprises a connector configured to be connected to a counter connector of a drive unit of the medicament delivery device via a predetermined rotation between the connector and the counter connector when the rotator is rotated from the first position to the second position such that the body is configured to be fixedly attached to the drive unit of the medicament delivery device. One of the body and the rotator comprises aprotrusion, and the other one of the body and the rotator comprises an interacting surface configured to interact with the protrusion when the rotator is rotated from the first position to the second position such that a tactile indication is generated between the protrusion and the interacting surface.

[0015] The sub-assembly of this disclosure can therefore provide a tactile indication to guide a user to properly attach the cassette to the drive unit. Furthermore, as the structural desgin is placed on the cassette rather than on the drive unit, tactile indication can be easily customized based on different medicament contained within the different cassette respectively. In this case, the drive unit can be standardized for all cassettes containing different medicament respectively.

[0016] Preferably, according to another embodiment, an audible indication is also generated between the protrusion and the interacting surface when the rotator is rotated from the first position to the second position.

[0017] Preferably, according to another embodiment, the connection between the connector and the counter connector is a bayonet connection or a thread connection.

[0018] Preferably, according to another embodiment, the connection between the connector and the counter connector is a bayonet connection.

[0019] Preferably, according to another embodiment, the connector is a bayonet protrusion.

[0020] Preferably, according to another embodiment, the body comprises the bayonet protrusion.

[0021] Preferably, according to another embodiment, the rotator is a ring enclosing a section of the body.

[0022] Preferably, according to another embodiment, the section of the body comprises the interacting surface.

[0023] Preferably, according to another embodiment, the ring comprises a ring body and the protrusion extending from an inner surface of the ring body towards the interacting surface.Preferably, according to another embodiment, the interacting surface extends in a circumferential direction around the longitudinal axis.

[0024] Preferably, according to another embodiment, the interacting surface is in contact with the protrusion during the rotation between the rotator and the body such that tactile indication is generated due to the resistance between the interacting surface and the protrusion.

[0025] Preferably, according to another embodiment, the interacting surface extends in a direction transverse to the longitudinal axis; the interacting surface is in contact with the protrusion during the rotation between the rotator and the body such that tactile indication is generated when the protrusion snaps over the interacting surface.

[0026] Preferably, according to another embodiment, the sub-assembly comprises a delivery member guard coaxially attached to the body and being axially movable relative to the body along the longitudinal axis.

[0027] Preferably, according to another embodiment, the rotator is rotatable relative to the delivery member guard between a locked position and an unlocked position.

[0028] Preferably, according to another embodiment, the rotator comprises a distally directed surface adjacent to a proximally directed surface of the delivery member guard in the locked position.

[0029] Preferably, according to another embodiment, wherein the distally directed surface of the rotator is spaced apart in a circumferential direction relative to the longitudinal axis from the proximally directed surface of the delivery member guard in the unlocked position.

[0030] Preferably, according to another embodiment, the rotator is engaged with the delivery member guard in a circumferential direction such that the rotation of the rotator relative to the body causes the delivery member guard to rotate relative to the body.

[0031] Preferably, according to another embodiment, the sub-assembly comprises a biasing member arranged between a distally directed surface of the delivery member guard and a proximally directed surface of the body.Preferably, according to another embodiment, the body comprises a flange configured to be in contact with a proximal edge.

[0032] Preferably, according to another embodiment, both the connector and the rotator are positioned distally to the flange.

[0033] Generally, all terms used in the claims are to be interpreted according to their ordinary meaning in the technical field, unless explicitly defined otherwise herein. All references to "a / an / the element, apparatus, component, means, etc.” are to be interpreted openly as referring to at least one instance of the element, apparatus, component, means, etc., unless explicitly stated otherwise.

[0034] BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Embodiments of the inventive concept will now be described, by way of example only, with reference to the accompanying drawings, in which:

[0036] Fig. 1 schematically shows a perspective view of a medicament delivery device comprising a drive unit and a cassette comprising a sub-assembly of the disclosure;

[0037] Fig. 2 schematically shows a perspective view of the medicament delivery device of Fig. 1 when the cassette is inserted to the drive unit, but is not yet fixedly attached to the drive unit;

[0038] Fig. 3 schematically shows a perspective view of the medicament delivery device of Fig. 1 when the cassette is rotated relative to the drive unit, so that the cassette is fixedly attached to the drive unit;

[0039] Fig. 4 schematically shows a cross-section view of the sub-assembly of the disclosure when a rotator is in a first position;

[0040] Fig. 5 schematically shows a cross-section view of the sub-assembly of the disclosure when the rotator is in a second position;

[0041] Figs 6A-6B schematically show perspective views of the rotator of Fig. 4 in different embodiments;

[0042] Fig. 7 schematically shows a perspective view of a delivery member guard of the sub-assembly of the disclosure and the rotator of Fig. 6B;Figs 8-9 schematically show perspective views of interaction between the delivery member guard of Fig. 7 and the rotator of Fig. 6B;

[0043] Fig. 10 schematically shows a perspective view of a delivery member guard of the sub-assembly of the disclosure and the rotator of Fig. 6A;

[0044] Figs 11-12 schematically show perspective views of interaction between the delivery member guard of Fig. 10 and the rotator of Fig. 6A;

[0045] Fig. 13 schematically shows a perspective view of a cassette of the medicament delivery device of Fig. 1;

[0046] Figs 14-16 schematically show perspective views of components of the cassette of Fig. 13;

[0047] Fig. 17 schematically shows a perspective view of a cap of the sub-assembly of the disclosure and a delivery member guard of the sub-assembly of the disclosure;

[0048] Figs 18-19 schematically show perspective views of the delivery member guard of Fig. 17 and the rotator of Fig. 4 in another embodiment.

[0049] DETAILED DESCRIPTION

[0050] Figs 1-19 illustrate a sub-assembly of a cassette 2 of a medicament delivery device. The sub-assembly comprises a body 20 extending along a longitudinal axis L between a proximal end and a distal end, as shown in Fig. 1. A rotator 22 attached to the body 20 and being rotatable relative to the body 20 around the longitudinal axis L from a first position to a second position. The body 20 is configured to accommodate a medicament container containing medicament. The medicament container can be a cartridge, a syringe or a flexible bag. Preferably, the body 20 can be formed in a similar shape to the medicament container. For example, the body 20 can be generally tubular shape. Thus, the cassette can be compact. In one example, the body 20 comprises a window 20a to enable the user to observe the medicament within the medicament container. The window can be an opening, or a section made of transparent material and be lined up with the medicament container within the body 20. In another example, the sub-assembly comprises a cap 3 attached to the proximal end of the body 20. The cap 3 is configured to be removed from the body 20 by the user before use the medicament delivery device. The cap 3is configured to cover a medicament delivery member integral to the medicament container or a nozzle of the medicament container configured to receive a medicament delivery member.

[0051] The rotator 22 can be a ring or a circlip so that the rotator 22 can be rotated around the longitudinal axis L relative to the body 20. In one example, the rotator 22 is configured to enclose a section of the body 20, as shown in Fig. 1. In one example, the rotator 22 is a ring-shaped component.

[0052] One of the body 20 and the rotator 22 comprises a connector 21 configured to be connected to a counter connector 11 of a drive unit 1 of the medicament delivery device via a predetermined rotation between the connector 21 and the counter connector 11 when the rotator 22 is rotated from the first position to the second position such that the body 20 is configured to be fixedly attached to the drive unit 1 of the medicament delivery device. In one example, as shown in Fig. 1, In one example, the connector 21 and the counter connector 11 are configured to form a bayonet connection. In one example, the connector 21 is a bayonet protrusion 21 extending from the body 20, preferably, from the distal end of the body 20. In this example, the counter connector 11 is a bayonet track configured to receive the protrusion 21 of the body 20. Alternatively, or additionally, the connector and the counter connector are configured to form a thread connection. Alternatively, or additionally, the connector is positioned on the rotator, e.g., on an outer surface of the rotator. As the rotator 22 is rotatable to the body 20, when the body 20 is rotated relative to the drive unit to fixedly attached the body 20 to the drive unit 1, as long as the rotator 22 is not subjected to a torque around the longitudinal axis L, the relative rotation between the rotator and the body is generated.

[0053] In one example where the connector 21 extends from the body 21, the rotator 22 is preferably designed to be inaccessible by the user when the body 20 is attached to the drive unit 1. For example, as shown in Fig. 1, the body 20 comprises a flange 20c configured to be in contact with a proximal edge 12 of the drive unit 1. In this example, both the connector 21 and the rotator 22 are positioned distally to the flange 20c, as shown in Fig. 1. Thus, when the body 20 is inserted to the drive unit 1 to a position that the connector 21 is engaged with the counter connector 11, the flange 20c of the body 20 is in contact to the proximal end of the drive unit 1. Thus, the user cannot access to the rotator 22. Thus, when the body 20 is rotated relativeto the drive unit to fixedly attached the body 20 to the drive unit 1, the relative rotation between the rotator and the body is generated. As a result, the rotator is rotated relative to the body from the first position to the second position.

[0054] Alternatively, or additionally, instead of the body 20 comprising the flange 20c, the rotator can be positioned within the body 20 to preventing the rotator from being accessed by the user.

[0055] In one example where the body 20 comprises the connector 21, the body 20 is configured to be fixedly attached to the drive unit 1 by the user rotating the body 20 relative to the drive unit 1 (the arrow R, as shown in Fig. 2).

[0056] One of the body 20 and the rotator 22 comprises a protrusion 221, and the other one of the body 20 and the rotator 22 comprises an interacting surface 211a, 211b configured to interact with the protrusion 221 when the rotator 22 is rotated from the first position to the second position such that a tactile indication is generated between the protrusion 221 and the interacting surface 211a, 211b, as shown in Figs 4-5.

[0057] In one example where the rotator 22 is a ring enclosing a section of the body 20. The section of the body 20 comprises the interacting surface 211a, 211b. The ring 22 comprises a ring body 220 and the protrusion extending from an inner surface of the ring body 220 towards the interacting surface 211a, 211b. In one example, the interacting surface 211a, 211b extends in a circumferential direction around the longitudinal axis L. The interacting surface 211a, 211b is in contact with the protrusion 221 during the rotation between the rotator 22 and the body 20 such that tactile indication is generated due to the resistance between the interacting surface 211a, 211b and the protrusion 221. In this example, the interacting surface 211a, 211b comprises a first section 211a configured to generate a high resistance when the protrusion 221 moves along the first section 211a and a second section 211b configured to generate a lower resistance than the first section 211a when the protrusion 221 moves along the second section 211b. For example, the first section 211a can be made of material can generate high friction and / or the second section is a recess to avoid or minimize being contact by the protrusion 221. As a result, when the user rotates the body 20 relative to the drive unit 1 in the rotational direction R to fixedly attach the body 20 to the drive unit 1 , the user needs to apply a higher torque followed by a lower torque to indicate the user that the body 20 isproperly attached to the drive unit 1. Furthermore, as the user needs to overcome the high resistance before the body 20 is properly attached to the drive unit 1, it also prevents the user attaches the body 20 to the drive unit 1 unintentionally, e.g., the user is observing the device but not yet planning to start the medicament delivery operation.

[0058] In one example, the interacting surface extends in a direction transverse to the longitudinal axis. The interacting surface is in contact with the protrusion when relative rotation happened between the rotator and the body such that tactile indication is generated when the protrusion snaps over the interacting surface. For example, the interacting surface comprises ratchet teeth configured to be interacted with the protrusion. In this example, a tactile and audible indication can be generated during the rotation between the rotator and the body.

[0059] In one example, the rotator 22 can be used to provide other functions to the subassembly. For example, the sub-assembly comprises a delivery member guard 4 coaxially attached to the body 20 and being axially movable relative to the body 20 along the longitudinal axis L. The delivery member guard comprises a proximal portion 410 configured to be in contact with a medicament delivery site during use of the medicament delivery device.

[0060] In one example, the rotator 22 is rotatable relative to the delivery member guard 4 between a locked position and an unlocked position. In this example, the rotation of the rotator 22 from the locked position to the unlocked position relative to the body 20 is configured to enable an axial movement of the delivery member guard 4. In one example, the locked position is the first position, and the unlocked position is the second position. In one example, the rotation of the rotator 22 from the locked position to the unlocked position relative to the body 20 is configured to enable a proximal movement of the delivery member guard 4 the rotator 22 comprises a distally directed surface 222; 222’ adjacent to a proximally directed surface 411; 41 T of the delivery member guard 4 in the locked position, as shown in Fig. 8 and Fig. 11; and the distally directed surface 222; 222’ of the rotator 22 is spaced apart in the circumferential direction relative to the longitudinal axis L from the proximally directed surface 411 ; 41 T of the delivery member guard 4 in the unlocked position, as shown in Fig. 9 and Fig. 12. In one example, the distally directed surface 222’ is formed on a ledge extending from the inner surface of the rotator 22, as shown inFig. 6A. Alternatively, or additionally, the distally directed surface is formed on a helical ledge 222 extending from the inner surface of the rotator 22, as shown in Fig.

[0061] 6B. The proximal movement of the delivery member guard 4 can be used to enable the cap assembly 3’ removal of the sub-assembly. In one example, the subassembly comprises a cap assembly 3’, as shown in Figs 14-16. The cap assembly 3’ comprises a user-accessible outer cap 30, a user-inaccessible inner cap 31, and a clutch ring 32 position between the outer cap 30 and the inner cap 31. In one example, the inner cap 31 is theadly engaged to the body 20 of the sub-assembly. The inner cap is axially fixed to the outer cap via a proximal engagement 311 and a counter engagement 302 of the outer cap. The inner cap 31 is rotationally fixed to a distal ring 322 of the clutch ring 32 via a rotational engagement 312. The clutch ring 32 comprises a spring 320 positioned between the outer cap 30 and the proximal section 410 of the delivery member guard 4. In this example, the outer cap 30 comprises ratchet teeth 301 configured to be engaged with a protrusion extending from the distal ring of the clutch ring 32 when the spring 320 is compressed between the outer cap 30 and proximal section 410 of the delivery member guard 4. In this example, the proximal movement of the delivery member guard 4 is configured to compress the spring 320, thus, enable the outer cap 30 to be coupled to the inner cap 31 and thus, the user can remove both the inner cap 31 and the outer cap 30 by rotating the outer cap 30 relative to the body 20.

[0062] In another example, the rotator 22 is engaged with the delivery member guard 4’ in the circumferential direction, as shown in Figs 18-19 such that the rotation of the rotator 22 relative to the body 20 causes the delivery member guard 4’ to rotate relative to the body 20. In one example, the rotator 22 comprises a first abutment 224 and the delivery member guard 4’ comprises a first counter abutment 412 configured to engaged with the first abutment 224 in the circumferential direction as shown in Fig. 19. In this example, the rotation of the delivery member guard 4 can be used to unlock the cap 3 so that the cap 3 can be removed from the body 20 before use of the medicament delivery device. For example, the cap 3 comprises an axial ledge 31 and a transverse ledge 32. The proximal end 410’ of the delivery member guard 4’ comprises a rib 410a’ the rib 410’ is configured to be engaged with the axial ledge 31 and the transverse ledge 32. As a result, the cap 3 cannot be removed from the proximal end 410’ of the delivery member guard 4 before the rotation of the delivery member guard 4 relative to the cap 3 by the rotator 22.In one example, the sub-assembly comprises a biasing member arranged between a distally directed surface of the delivery member guard 4 and a proximally directed surface of the body 20.

[0063] Furthermore, the body 20, as mentioned in any example, may be provided with (i.e. , molded in, molded with) a compound featuring persistently antimicrobial, antifungal, and / or antiviral properties. Alternatively, a compound featuring persistently antimicrobial, antifungal, and / or antiviral properties may be applied to the molded (i.e., finished) components through secondary processes (e.g., chemical vapor deposition), spraying, or dipping processes. The housing can be one single component or formed by multiple components being assembled dependent on the manufacture process. Similarly, the delivery member guard and / or the plunger rod / and / or the actuator can be one single component respectively or formed by multiple components being assembled respectively dependent on the manufacture process.

[0064] The medicament delivery devices described herein can be used for the treatment and / or prophylaxis of one or more of many different types of disorders. Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia, diabetes (e.g. type 2 diabetes), psoriasis, migraines, multiple sclerosis, anaemia, lupus, atopic dermatitis, asthma, nasal polyps, acute hypoglycaemia, obesity, anaphylaxis and allergies. Exemplary types of medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, antibodies, antibody-drug conjugates, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, protein analogues, protein variants, protein precursors, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies and / or protein derivatives.

[0065] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to (with non-limiting examples of relevant disorders in brackets): etanercept (rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis)), evolocumab (hypercholesterolaemia), exenatide (type 2 diabetes), secukinumab (psoriasis), erenumab (migraines), alirocumab (rheumatoid arthritis), methotrexate (amethopterin) (rheumatoid arthritis), tocilizumab (rheumatoid arthritis), interferon beta-1a (multiple sclerosis), sumatriptan (migraines), adalimumab (rheumatoidarthritis), darbepoetin alfa (anaemia), belimumab (lupus), peginterferon beta-1a' (multiple sclerosis), sarilumab (rheumatoid arthritis), semaglutide (type 2 diabetes, obesity), dupilumab (atopic dermatitis, asthma, nasal polyps, allergies), glucagon (acute hypoglycaemia), epinephrine (anaphylaxis), insulin (diabetes), atropine and vedolizumab (inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis)) , ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, famtrastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibritumomab tiuxetan, isatuximab, mogamulizumab, moxetumomab pasudotox, obinutuzumab, ofatumumab, olaratumab, panitumumab, polatuzumab vedotin, ramucirumab, sacituzumab govitecan, tafasitamab, or margetuximab. Pharmaceutical formulations including, but not limited to, any drug described herein are also contemplated for use in the medicament delivery devices described herein, for example, pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier. Pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) may include one or more other active ingredients, or may be the only active ingredient present.

[0066] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, an immuno-oncology or biooncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, enzymes, signaling proteins, pro-apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.

[0067] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as HER-2 receptor modulators, interleukin modulators, interferon modulators, CD38 modulators, CD22 modulators, CCR4 modulators, VEGF modulators, EGFR modulators, CD79b modulators, Trop-2 modulators, CD52 modulators, BCMA modulators, PDGFRA modulators, SLAMF7 modulators, PD-1 / PD-L1 inhibitors / modulators, B-lymphocyte antigen CD19 inhibitors, B-lymphocyte antigen CD20 modulators, CD3 modulators, CTLA-4 inhibitors, TIM-3 modulators,VISTA modulators, INDO inhibitors, LAG3 (CD223) antagonists, CD276 antigen modulators, CD47 antagonists, CD30 modulators, CD73 modulators, CD66 modulators, CDw137 agonists, CD158 modulators, CD27 modulators, CD58 modulators, CD80 modulators, CD33 modulators, APRIL receptor modulators, HLA antigen modulators, EGFR modulators, B-lymphocyte cell adhesion molecule modulators, CDw123 modulators, Erbb2 tyrosine kinase receptor modulators, mesothelin modulators, HAVCR2 antagonists, NY-ESO-1 0X40 receptor agonist modulators, adenosine A2 receptors, ICOS modulators, CD40 modulators, TIL therapies, or TOR therapies.

[0068] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOX7, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini-CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, I VAC, HyperCVAD, R-HyperCVAD, SC-EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX, CALGB 8811, HIDAC, MOpAD, 7 + 3, 5 +2, 7 + 4, MEC, CVP, RBAC500, DHA-Cis, DHA-Ca, DHA-Ox, RCVP, RCEPP, RCEOP, CMV, DDMVAC, GemFLP, ITP, VIDE, VDC, VAI, VDC-IE, MAP, PCV, FCR, FR, PCR, HDMP, OFAR, EMA / CO, EMA / EP, EP / EMA, TP / TE, BEP, TIP, VIP, TPEx, ABVD, BEACOPP, AVD, Mini-BEAM, IGEV, C-MOPP, GCD, GEMOX, CAV, DT-PACE, VTD-PACE, DCEP, ATG, VAC, VelP, OFF, GTX, CAV, AD, MAID, AIM, VAC-IE, ADOC, or PE.

[0069] Exemplary medicaments that could be included in the medicament delivery devices described herein include, but are not limited to, those used for chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid. Exemplary chemotherapy medicaments include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed,mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.

[0070] The inventive concept has mainly been described above with reference to a few examples. However, as is readily appreciated by a person skilled in the art, other embodiments than the ones disclosed above are equally possible within the scope of the inventive concept, as defined by the appended claims.

Claims

CLAIMS1. A sub-assembly of a cassette of a medicament delivery device, the subassembly comprising:a body (2) extending along a longitudinal axis (L) between a proximal end and a distal end;a rotator (22) attached to the body (2) and being rotatable relative to the body (2) around the longitudinal axis (L) from a first position to a second position; wherein one of the body (2) and the rotator (22) comprises a connector (21) configured to be connected to a counter connector (11) of a drive unit (1) of the medicament delivery device via a predetermined rotation between the connector (21) and the counter connector (11) when the rotator (21) is rotated from the first position to the second position such that the body (2) is configured to be fixedly attached to the drive unit (1) of the medicament delivery device; and wherein one of the body (2) and the rotator (22) comprises a protrusion (221), and the other one of the body (2) and the rotator (22) comprises an interacting surface (211a, 211b) configured to interact with the protrusion (221) when the rotator (22) is rotated from the first position to the second position such that a tactile indication is generated between the protrusion (221) and the interacting surface (211a, 211b).

2. The sub-assembly according claim 1 , wherein the connection between the connector and the counter connector is a bayonet connection or a thread connection.

3. The sub-assembly according claim 2, wherein the connection between the connector and the counter connector is a bayonet connection; and wherein the connector is a bayonet protrusion.

4. The sub-assembly according to claim 3, wherein the body comprises the bayonet protrusion.

5. The sub-assembly according to any one of the proceeding claims, wherein the rotator is a ring enclosing a section of the body.

6. The sub-assembly according to claim 5, wherein the section of the body comprises the interacting surface; wherein the ring comprises a ring body and the protrusion extending from an inner surface of the ring body towards the interacting surface.

7. The sub-assembly according to any one of the proceeding claims, wherein the interacting surface extends in a circumferential direction around the longitudinal axis; wherein the interacting surface is in contact with the protrusion during the rotation between the rotator and the body such that tactile indication is generated due to the resistance between the interacting surface and the protrusion.

8. The sub-assembly according to any one of the proceeding claims, wherein the interacting surface extends in a direction transverse to the longitudinal axis; wherein the interacting surface is in contact with the protrusion during the rotation between the rotator and the body such that tactile indication is generated when the protrusion snaps over the interacting surface.

9. The sub-assembly according to any one of the preceding claims, the subassembly comprises a delivery member guard coaxially attached to the body and being axially movable relative to the body along the longitudinal axis.

10. The sub-assembly according to claim 9, wherein the rotator is rotatable relative to the delivery member guard between a locked position and an unlocked position;wherein the rotator comprises a distally directed surface adjacent to a proximally directed surface of the delivery member guard in the locked position; and wherein the distally directed surface of the rotator is spaced apart in a circumferential direction relative to the longitudinal axis from the proximally directed surface of the delivery member guard in the unlocked position.

11. The sub-assembly according to claim 9, wherein the rotator is engaged with the delivery member guard in a circumferential direction such that the rotation of the rotator relative to the body causes the delivery member guard to rotate relative to the body.1712. The sub-assembly according to any one of claims 9-11 , wherein the subassembly comprises a biasing member arranged between a distally directed surface of the delivery member guard and a proximally directed surface of the body.

13. The sub-assembly according to any one of the preceding claims, wherein the body comprises a flange configured to be in contact with a proximal edge; wherein both the connector and the rotator are positioned distally to the flange.

Images